Rosetta Genomics Ltd (ROSG) - Product Pipeline Analysis, 2017 Update

Date: July 14, 2017
Pages: 42
Price:
US$ 750.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RBA51EB384EEN
Leaflet:

Download PDF Leaflet

Rosetta Genomics Ltd (ROSG) - Product Pipeline Analysis, 2017 Update
Summary

Rosetta Genomics Ltd (RGL) is a developer of next generation diagnostic tests for personalized medicine. The company provides testing services such as cancer origin, next-gen, thyroid, lung, prostate, bladder, breast, kidney and specialty tests. It also develops tests for thyroid neoplasia, oncology, kidney rejection, Alzheimer's disease, therapeutics and CMV. The company offers RosettaGX platform on the cutting edge of molecular science and genomic testing technologies, with tests. It operates in Australia, New Zealand, Israel, Singapore, Canada, Greece, India, Saudi Arabia, Qatar, the UAE, Israel and Turkey. RGL is headquartered in Rehovot, Israel.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Rosetta Genomics Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Rosetta Genomics Ltd Company Overview
Rosetta Genomics Ltd Company Snapshot
Rosetta Genomics Ltd Pipeline Products and Ongoing Clinical Trials Overview
Rosetta Genomics Ltd – Pipeline Analysis Overview
Rosetta Genomics Ltd - Key Facts
Rosetta Genomics Ltd - Major Products and Services
Rosetta Genomics Ltd Pipeline Products by Development Stage
Rosetta Genomics Ltd Pipeline Products Overview
Bladder Cancer Prognostic Assay
Bladder Cancer Prognostic Assay Product Overview
Body Fluids-Based Diagnostic Test - Cancer
Body Fluids-Based Diagnostic Test - Cancer Product Overview
microRNA Test - Alzheimer’s Disease
microRNA Test - Alzheimer’s Disease Product Overview
microRNA Test - Bladder Cancer Risk Stratification
microRNA Test - Bladder Cancer Risk Stratification Product Overview
microRNA Test - Endometrial Cancer Stratification
microRNA Test - Endometrial Cancer Stratification Product Overview
microRNA Test - Gastric Cancer Recurrence
microRNA Test - Gastric Cancer Recurrence Product Overview
microRNA Test - Heart Failure
microRNA Test - Heart Failure Product Overview
microRNA Test - Ovarian Cancer
microRNA Test - Ovarian Cancer Product Overview
microRNA Test - Preeclampsia
microRNA Test - Preeclampsia Product Overview
microRNA-Based Assay - Chronic Allograft Dysfunction
microRNA-Based Assay - Chronic Allograft Dysfunction Product Overview
microRNA-Based Assay - Neuromuscular Diseases
microRNA-Based Assay - Neuromuscular Diseases Product Overview
microRNA-Based Assay - Neuromuscular Dystrophies
microRNA-Based Assay - Neuromuscular Dystrophies Product Overview
microRNA-Based Diagnostic Test - Melanoma
microRNA-Based Diagnostic Test - Melanoma Product Overview
miRscreen Test - Colon Cancer
miRscreen Test - Colon Cancer Product Overview
Prelude DCIS - Breast Cancer
Prelude DCIS - Breast Cancer Product Overview
ROS1 Lung Cancer Biomarker Assay
ROS1 Lung Cancer Biomarker Assay Product Overview
RosettaGX Reveal - Second Version
RosettaGX Reveal - Second Version Product Overview
Rosetta Genomics Ltd - Key Competitors
Rosetta Genomics Ltd - Key Employees
Rosetta Genomics Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Rosetta Genomics Ltd, Recent Developments
Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China
May 05, 2017: Rosetta Genomics Expands International Access for RosettaGX Reveal through Agreement with Cytolog Laboratories in Brazil
May 02, 2017: Rosetta Genomics to Increase Investment in RosettaGX Reveal and Explore Strategic Alternatives for the PersonalizeDx Business
May 01, 2017: Rosetta Genomics Expands Patent Portfolio in Europe and Japan
Mar 30, 2017: Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results
Mar 20, 2017: Rosetta Genomics Fortifies Patent Protection For Its Unique RosettaGX Reveal Assay
Feb 07, 2017: Rosetta Genomics Reports Preliminary RosettaGX Reveal Financial Results for the 2016 Fourth Quarter and Year
Feb 06, 2017: Rosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx RevealTM microRNAs
Oct 27, 2016: Clinical Validation Study for RosettaGX Reveal Published in the Journal of Clinical Pathology
Oct 24, 2016: RosettaGX Reveal Analytical Validation Study Featured on the Cover of the October Issue of Cancer Cytopathology
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Rosetta Genomics Ltd Pipeline Products and Ongoing Clinical Trials Overview
Rosetta Genomics Ltd Pipeline Products by Equipment Type
Rosetta Genomics Ltd Pipeline Products by Indication
Rosetta Genomics Ltd, Key Facts
Rosetta Genomics Ltd, Major Products and Services
Rosetta Genomics Ltd Number of Pipeline Products by Development Stage
Rosetta Genomics Ltd Pipeline Products Summary by Development Stage
Bladder Cancer Prognostic Assay - Product Status
Bladder Cancer Prognostic Assay - Product Description
Body Fluids-Based Diagnostic Test - Cancer - Product Status
Body Fluids-Based Diagnostic Test - Cancer - Product Description
microRNA Test - Alzheimer’s Disease - Product Status
microRNA Test - Alzheimer’s Disease - Product Description
microRNA Test - Bladder Cancer Risk Stratification - Product Status
microRNA Test - Bladder Cancer Risk Stratification - Product Description
microRNA Test - Endometrial Cancer Stratification - Product Status
microRNA Test - Endometrial Cancer Stratification - Product Description
microRNA Test - Gastric Cancer Recurrence - Product Status
microRNA Test - Gastric Cancer Recurrence - Product Description
microRNA Test - Heart Failure - Product Status
microRNA Test - Heart Failure - Product Description
microRNA Test - Ovarian Cancer - Product Status
microRNA Test - Ovarian Cancer - Product Description
microRNA Test - Preeclampsia - Product Status
microRNA Test - Preeclampsia - Product Description
microRNA-Based Assay - Chronic Allograft Dysfunction - Product Status
microRNA-Based Assay - Chronic Allograft Dysfunction - Product Description
microRNA-Based Assay - Neuromuscular Diseases - Product Status
microRNA-Based Assay - Neuromuscular Diseases - Product Description
microRNA-Based Assay - Neuromuscular Dystrophies - Product Status
microRNA-Based Assay - Neuromuscular Dystrophies - Product Description
microRNA-Based Diagnostic Test - Melanoma - Product Status
microRNA-Based Diagnostic Test - Melanoma - Product Description
miRscreen Test - Colon Cancer - Product Status
miRscreen Test - Colon Cancer - Product Description
Prelude DCIS - Breast Cancer - Product Status
Prelude DCIS - Breast Cancer - Product Description
ROS1 Lung Cancer Biomarker Assay - Product Status
ROS1 Lung Cancer Biomarker Assay - Product Description
RosettaGX Reveal - Second Version - Product Status
RosettaGX Reveal - Second Version - Product Description
Rosetta Genomics Ltd, Key Employees
Rosetta Genomics Ltd, Other Locations
Rosetta Genomics Ltd, Subsidiaries
Glossary

LIST OF FIGURES

Rosetta Genomics Ltd Pipeline Products by Equipment Type
Rosetta Genomics Ltd Pipeline Products by Development Stage

COMPANIES MENTIONED

Protalix BioTherapeutics Inc
Kadimastem Ltd
Hadasit Bio-Holdings Ltd
Compugen Ltd
Skip to top


Ask Your Question

Rosetta Genomics Ltd (ROSG) - Product Pipeline Analysis, 2017 Update
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: